LeMaitre Vascular, Inc. reported $241M of revenue over the trailing twelve months. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $241M (to Q3 2025). Net income: $66M, trailing twelve months to Q2 2026. Free cash flow: $74M, trailing twelve months to Q2 2026. Operating margin: 26%, trailing twelve months to Q3 2025.

LMATLeMaitre Vascular, Inc.

Healthcare

$80.67-12% 1Y

$80.67

$78.6652 weeks$117.10

LMAT as reported

LeMaitre Vascular, Inc. reported $241M of revenue over the trailing twelve months. 11 reported series are charted on this page, each one as filed.

$241M

Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied

Net income: $66M
Net income · +39% year on year · trailing twelve months to Q2 2026
Free cash flow: $74M
Free cash flow · +41% year on year · trailing twelve months to Q2 2026
Operating margin: 26%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for LMAT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$241M	n/a	Q3 2025
Net income	$66M	+39%	Q2 2026
EPS	$2.85	+39%	Q2 2026
Gross margin	71%	n/a	Q3 2025
Operating margin	26%	n/a	Q3 2025
Net margin	22%	n/a	Q3 2025
ROE	15%	n/a	Q2 2026
ROA	9.6%	n/a	Q2 2026
ROIC	16%	n/a	Q4 2021 · 18 quarters behind
Free cash flow	$74M	+41%	Q2 2026
P/E	28.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.